Bristol-Myers Squibb Overview
Latest ROE for Bristol-Myers Squibb: 41.59% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow41.59%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, BMY shows a ROE of 41.59%. That is above the Healthcare sector average of 21.28%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about 21.28%. Bristol-Myers Squibb is at 41.59%, which is higher that average. That is roughly 95.4% above the sector mean. Use the comparison chart on this page to see how BMY stacks up against individual peers as well.
Check the historical chart to see whether BMY's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Bristol-Myers Squibb with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Bristol-Myers Squibb's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 41.59%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about 21.28%, while BMY is at 41.59%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
